specialty manufacturing in Texas and a next-generation manufacturing plant for biologics in Maryland, according to the drugmaker. While AstraZeneca's U.S. operations generate around 43% of its ...

AstraZeneca Plc (NASDAQ:AZN) is reportedly reconsidering its planned $578.4 million (450 million pounds) investment in a new vaccine-manufacturing site, a departure from CEO Pascal Soriot‘s ...

AstraZeneca has cancelled a planned £450 million investment in a vaccine manufacturing plant in Merseyside, saying Labour ...

The Anglo-Swedish drug firm opened the plant in Rockville ... “The Rockville facility will be central to AstraZeneca’s production of next-generation cell therapies, including CAR-T therapies.

A multi-million dollar vaccine plant being built in the U.K. by AstraZeneca is under threat amid reports the Treasury could cut the state aid being offered to support it, The Telegraph telegraphs.

LONDON, Feb 27 (Reuters) - AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its research and development and drug manufacturing ...

Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech. AstraZeneca is ...

AstraZeneca canceled its £450 million vaccine manufacturing plant in Liverpool after rejecting a £78 million government funding offer. The company raised concerns over NHS drug pricing policies ...

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Merseyside, blaming a reduction in government support. The pharmaceutical giant announced its decision ...

“Several factors have influenced this decision, including the timing and reduction of the final offer compared to the previous government’s proposal,” read a statement by AstraZeneca.

AstraZeneca established its vaccines unit after collaborating with the University of Oxford to develop a COVID-19 vaccine. The existing site, currently used for producing the nasal flu vaccine ...